| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 68.593 | 138.915 | 212.802 | 402.491 | 527.883 | 687.401 | 704.700 |
| Total Income - EUR | - | - | - | 68.594 | 147.684 | 218.381 | 407.532 | 527.887 | 687.403 | 704.704 |
| Total Expenses - EUR | - | - | - | 67.836 | 141.545 | 206.943 | 361.836 | 504.940 | 664.594 | 681.979 |
| Gross Profit/Loss - EUR | - | - | - | 757 | 6.140 | 11.439 | 45.696 | 22.947 | 22.810 | 22.725 |
| Net Profit/Loss - EUR | - | - | - | 72 | 4.725 | 9.437 | 42.147 | 18.407 | 14.810 | 17.918 |
| Employees | - | - | - | 3 | 0 | 6 | 5 | 9 | 6 | 7 |
Check the financial reports for the company - Herbapharm D&B S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 2.434 | 1.336 | 20.932 | 37.463 | 79.025 | 127.177 | 115.263 |
| Current Assets | - | - | - | 49.795 | 56.823 | 108.625 | 199.138 | 238.363 | 357.404 | 320.617 |
| Inventories | - | - | - | 31.983 | 39.972 | 75.841 | 35.395 | 92.771 | 119.729 | 157.840 |
| Receivables | - | - | - | 14.270 | 13.057 | 27.828 | 46.905 | 77.755 | 197.397 | 116.933 |
| Cash | - | - | - | 3.543 | 3.794 | 4.955 | 116.837 | 67.838 | 40.278 | 45.843 |
| Shareholders Funds | - | - | - | 115 | 4.838 | 14.183 | 56.016 | 74.597 | 46.870 | 48.645 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 52.114 | 53.321 | 115.374 | 180.585 | 242.792 | 437.710 | 387.234 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Herbapharm D&B S.r.l.